Copy
The latest from ISAPP
View this email in your browser

ISAPP Newsletter – February 19, 2020


In February, we're just far enough into the new decade to start envisioning and planning for new directions in the scientific field of probiotics and prebiotics in the years ahead. But an important first step is to reflect on how far the field has come over the past ten years. That's why we begin this newsletter with perspectives from the ISAPP board members -- leading experts in the field -- on the progress that's been made in the field of probiotics and prebiotics since 2010.

Also in this newsletter is an important article concerning the submission of GRAS notices for bacterial strains to the US Food and Drug Administration (FDA).

And make sure you read Dr. Dan Merenstein's blog post about the importance of scrutinizing the evidence for any treatment that is widely seen as a ‘miracle cure’.

Check out our comprehensive resource on probiotics, aimed at health professionals, which covers the history of the probiotic concept as well as the evidence for efficacy (by indication) and safety.

The past decade of probiotics and prebiotics research: ISAPP board members share their perspectives

 
Rapid advancements in scientific tools and techniques for studying probiotics and prebiotics have occurred in the past decade. But in what ways has the field moved forward? In this blog post, the ISAPP board members summarize the last decade of probiotics and prebiotics research, explaining how the stage is set for the next decade of innovations.
 

The FDA’s view on the term “probiotics”

 
In this blog post, food and nutrition regulatory consultant James Heimbach writes about his recent experience submitting GRAS notices for four strains of bacteria -- and finding that the US Food and Drug Administration (FDA) no longer accepts the word “probiotics” in GRAS notices.
 

A Miracle Treatment! Or Not?

 
In this ISAPP blog post, Dr. Dan Merenstein urges us to take a look at our own biases by asking: What do we consider ‘good evidence’ for a treatment, and does the answer depend on the nature of that treatment? He describes the evidence supporting a much-discussed treatment for recurrent C. difficile infection and compares it to the evidence for the use of probiotics as a preventative measure.
 

The ISAPP quick guide to probiotics for health professionals: History, efficacy, and safety

Health professionals often have difficulty keeping up with the latest evidence on which probiotics are effective for which indications. ISAPP is pleased to offer a new comprehensive resource on probiotics for health professionals, which includes a summary of the evidence for probiotic use by indication and links to meta-analyses and other references. View this resource online or download it as a pdf.

To ensure you continue to receive these monthly newsletters without interruption, please add isappscience.org to your safe domains list and add info@isappscience.org to your safe senders list.
Keep in touch with ISAPP!
Twitter
Facebook
Website
Copyright © 2020 ISAPP, All rights reserved.
Our mailing address is:
ISAPP
3230 Arena Boulevard, Box 245-172
Sacramento, CA 95834

Add us to your address book


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list